Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
Crossref DOI link: https://doi.org/10.1186/s12883-016-0702-4
Published Online: 2016-09-17
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Cutter, Gary R.
Knappertz, Volker
Sasson, Nissim
Ladkani, David
Funding for this research was provided by:
Teva Pharmaceutical Industries
License valid from 2016-09-17